ECOR
electroCore, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-32.97
P/S
1.78
EV/EBITDA
-5.16
DCF Value
$-460.47
FCF Yield
-14.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
86.8%
Operating Margin
-41.1%
Net Margin
-43.6%
ROE
-2072.1%
ROA
-74.8%
ROIC
-171.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $9.2M | $-3.0M | $-0.38 |
| FY 2025 | $32.0M | $-14.0M | $-1.65 |
| Q3 2025 | $8.7M | $-3.4M | $-0.40 |
| Q2 2025 | $7.4M | $-3.7M | $-0.44 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.60
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.